This exploratory study is a follow up to our previous investigation of immune response in the circulation of high-grade Gleason 9 prostate cancer patients treated with EBRT+BT compared to EBRT alone.
Notably, EBRT+BT demonstrates the potential to elicit an effect on CD4/CD8 ratio which may attributed to improved clinical response to therapy. Our findings show promise for leveraging circulating immune cells as predictive biomarkers for radiotherapy response.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2024 Jan 02 [Epub ahead of print]
H Wang, L Mendez, G Morton, A Loblaw, H T Chung, P Cheung, A Mesci, V Escueta, T N Petchiny, X Huang, S D White, M Downes, D Vesprini, S K Liu
Department of Medical Biophysics, University of Toronto, Toronto, ON; Sunnybrook Research Institute, Toronto, ON., Division of Radiation Oncology, London Regional Cancer Program, London, ON., Sunnybrook Research Institute, Toronto, ON; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON; Department of Radiation Oncology, University of Toronto, Toronto, ON., Sunnybrook Research Institute, Toronto, ON; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON; Department of Radiation Oncology, University of Toronto, Toronto, ON; Institute of Health Policy, Management and Evaluation, Toronto, ON., Sunnybrook Research Institute, Toronto, ON; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON., Sunnybrook Research Institute, Toronto, ON., Division of Anatomic Pathology, Department of Laboratory Medicine and Molecular Diagnostics, Sunnybrook Health Sciences Centre, Toronto, ON., Department of Medical Biophysics, University of Toronto, Toronto, ON; Sunnybrook Research Institute, Toronto, ON; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, ON; Department of Radiation Oncology, University of Toronto, Toronto, ON. Electronic address: .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/38176656